Integrated analysis of 50 mg twice-weekly etanercept in patients with psoriasis from three phase 3 studies - 21/08/11
Stephen Tyring, MD, PhD, MBA, University of Texas Health Science Center, Houston, TX, United States; Craig Leonardi, MD, Saint Louis University, St. Louis, MO, United States; Kim Papp, MD, Probity Medical Research, Waterloo, ON, Canada; Angelika Jahreis, MD, PhD, Amgen, Inc., Thousand Oaks, CA, United States
Le texte complet de cet article est disponible en PDF. P2771 Dr. Tyring has performed research supported by Amgen, Inc. but has no Amgen stock or other financial interest in Amgen. Dr. Leonardi is on the Clinical Advisory Board and a member of the Speakers Bureau for Amgen, Inc.; he is also a principal investigator in clinical trials, but he owns no stock or financial interests in Amgen. Dr. Papp has no significant financial interest in Amgen or in any of its competitors. Research funded by Immunex Corporation, a wholly owned subsidiary of Amgen Inc., and by Wyeth Research |
Vol 52 - N° 3S
P. P189 - mars 2005 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?